



1616  
Patent Application  
Docket No. PC8835ETMC

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this 25<sup>th</sup> day of July, 2002.

By Deanna L Miller  
(Signature of person mailing)

RECEIVED

Deanna L. Miller  
(Typed or printed name of person)

AUG 06 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Kimberly O. Cameron, et al

COPY OF PAPERS  
ORIGINALLY FILED

APPLICATION NO.: 09/820,158

Examiner: Unknown

FILING DATE: March 28, 2001

Group Art Unit: 1616

TITLE: Estrogen Agonists/Antagonists for  
Preventing Breast Cancer

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Response

This is a response to the Office Action dated July 1, 2002, which contained only an election of species requirement.

Applicants hereby elect the compound of claim 3, which is (-)-cis-6-phenyl-5-[4-pyrrolydinyl-1-yl-ethoxy]-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol. The claims that read on the elected species are claims 1-4.

Applicants wish to note that claims to the compounds of formula I, including (-)-cis-6-phenyl-5-[4-pyrrolydinyl-1-yl-ethoxy]-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol, were allowed in U.S. Patent No. 5,552,412, of which the present application claims priority. Because the compounds of formula I are patentable, Applicants respectfully assert that the presently claimed methods of prevent breast cancer using the compounds is patentable.

Consideration and allowance of claims 1-4 is respectfully requested.

Date: 7/25/2002

By: Todd M. Crissey

Pfizer, Inc.  
Patent Department, MS: 8260-1611  
Eastern Point Road  
Groton, CT 06340  
Phone: (860) 715-4331  
Fax: (860) 441-5221

Todd M. Crissey  
Registration No. 37,807

#4  
HKO  
8-21-02